Business Context and Reporting Period
This Form 8-K was filed by Signal Genetics, Inc. (not Viridian Therapeutics, Inc.) on November 2, 2016, reporting events occurring on November 1, 2016. The filing discloses a joint conference call between Signal Genetics and Miragen Therapeutics, Inc. regarding a proposed merger. The registrant is incorporated in Delaware and headquartered in Carlsbad, CA.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate events rather than periodic financial performance data.
Material Changes
- Proposed Merger: Signal Genetics and Miragen Therapeutics are discussing a proposed merger, with details discussed in the attached conference call transcript (Exhibit 99.1).
- Asset Sale: Signal Genetics is attempting to enter into a definitive asset purchase agreement for the sale of its MyPRS test.
- Listing Status: The filing addresses expectations regarding Signal's continued listing on the NASDAQ Capital Market until the merger closes and the combined company's listing thereafter.
Guidance, Outlook, and Risks
Management provided forward-looking statements regarding the structure, timing, and completion of the proposed merger and financing. Key risks and contingencies include:
- Transaction Approval: Risks associated with obtaining stockholder approval and the ability to consummate the merger.
- Asset Sale Uncertainty: The ability to finalize the sale of the MyPRS test is not guaranteed.
- Cash Utilization: Uncertainty in projecting future cash needs for contingent liabilities and operations.
- Clinical and Regulatory Risks: Risks related to drug discovery, regulatory approval processes, and the potential that earlier study results may not predict future clinical trial outcomes.
- Intellectual Property: Risks regarding the protection and market exclusivity of Miragen's intellectual property.
The company explicitly disclaims any obligation to update these forward-looking statements.
Investor Verification Checklist
- Verify the definitive terms of the proposed merger between Signal Genetics and Miragen Therapeutics.
- Confirm the status of the asset purchase agreement for the MyPRS test.
- Review the combined company's projected capitalization and cash reserves to support future clinical trials.
- Assess the regulatory status and intellectual property portfolio of Miragen's product candidates (MRG-106 and MRG-201).
- Monitor stockholder voting outcomes required to approve the merger.